Financings in Brief: Sola International
This article was originally published in The Gray Sheet
Executive Summary
Sola International: Plans to submit registration statement to SEC for an offering of 2.8 mil. shares, including 2 mil. offered by the company and roughly 800,000 by selling shareholders. Proceeds from the offering, to be underwritten by Morgan Stanley and Merrill Lynch, will be used to repay debt expected to be incurred to finance Sola's recently announced acquisition of American Optical Corporation's ophthalmic eyeglass lens division ("The Gray Sheet" March 18, I&W-16)...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.